Relevant Disclosure is attached.
Awaiting price reaction for this filing.
Fortis Healthcare has submitted a quarterly disclosure on the use of proceeds from its listed Non-Convertible Debentures (NCDs) for Q4 FY25 (quarter ended March 31, 2025). The company raised Rs. 1,550 crore (155,000 NCDs of Rs. 1 lakh each) through a private placement on December 19, 2024. The entire amount was used for purchasing equity shares of Agilus Diagnostics Limited and related issue expenses, with Rs. 429.37 crore deployed on December 20, 2024 and Rs. 1,120.63 crore on January 16, 2025. The company confirms there is no deviation or variation from the stated purpose of fund utilization. BSR & Co. LLP, the statutory auditor, has issued an independent certificate confirming that the utilization statement is in agreement with the audited financial statements for FY25.
This is a routine SEBI-mandated compliance filing confirming that the NCD proceeds were used entirely for the disclosed purpose (Agilus Diagnostics acquisition) without any diversion. No material impact on shareholders or stock price is expected from this disclosure itself, as it simply confirms disciplined use of previously raised debt.